Technology evaluation: Abarelix, Praecis pharmaceuticals

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 5, 2000, Pages 579-585

  Doehn, C ^a   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; BICALUTAMIDE; GONADORELIN ANTAGONIST; LEUPRORELIN;

BREAST CANCER; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG STRUCTURE; ENDOCRINE DISEASE; ENDOMETRIOSIS; HUMAN; LICENSING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; SUSTAINED RELEASE PREPARATION; TECHNOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; ENDOMETRIOSIS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, LHRH;

EID: 0033735174     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Advances and trends in hormonal therapy for advanced prostate cancer
2. Synthelabo adopts new strategy in US
3. The magnitude of Lupron (L) or Zoladex (Z) testosterone and luteinizing hormone surge is dependent on formulation: Comparative results of L and Z versus Abarelix-Depot, a GnRH antagonist devoid of androgen
4. Abarelix-Depot, a sustained release formulation of a potent GnRH antagonist in patients with prostate cancer: Phase II clinical results and endocrine comparison with superagonists Lupron and Zoladex
5. Merrill Lynch: Pharmaceutical, Device and Biotechnology Bulletin
6. Aiming to become global top-10 company: Mr Guerin of Sanofi-Synthelabo
7. Merrill Lynch: Sanofi-Synthelabo
8. Management of hormone refractory prostate cancer: Current standards and future prospects
9. An analysis of watchful waiting for clinically localized prostate cancer
10. Incidence, etiology, location, prevention and treatment of positive surgical margins after redical prostatectomy for prostate cancer
11. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound reduction in testosterone and PSA in advanced prostate cancer patients (PrCa)
12. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound reduction in prostate gland volume (PGV) and androgen levels before brachytherapy (BT) or radiation therapy (XRT)
13. Abarelix-Depot (A-D) versus Leuprolide acetate (L) for prostate cancer: Results of a multi-institutional, ramdomized, phase III study in 271 patients
14. Abarelix-Depot (A-D) versus Leuprolide acetate (L) plus bicalutamide [Casodex (C)], for prostate cancer: Results of a multi-institutional, randomized, phase III study in 255 patients
15. Annual Report 1999 - Amgen Inc
16. The natural history of early prostate cancer and the impact of endocrine treatment
17. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal anti-androgens
18. Development of GnRH antagonists for prostate cancer: New approaches to treatment
19. Estrogens in the treatment of prostate cancer
20. Abarelix Depot, a pure GNRH antagonist, compared to LHRH agonist in patients with prostate cancer
21. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
22. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853
23. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
24. Hormonal therapy in the management of prostate cancer: From Huggins to the present
25. Combating prostate cancer
26. PSA kinetics: Rates of decline ere significantly more rapid following therapy with the GnRH antagonist Abarelix-Depot (A-D), compared to superagonists Lupron® (L) and Zoladex® (Z) in prostate cancer (PrCa) patients (pts)
27. Abarelix-Depot (A-D), a sustained-release (SR) formulation of a potent GnRH pure antagonist in patients (pts) with prostate cancer (PrCA): Phase II clinical results and endocrine comparison with superagonists Lupron® (L) and Zoladex® (Z)
28. Some aspects of the biology and endocrinology of prostate cancer
29. Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist
30. Evaluation and managament of the man who has failed primary curative therapy for prostate cancer
31. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
32. Controversies in the managament of advanced prostate cancer
33. Casodex(TM) 10-200 mg deily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies
34. Abarelix: Antineoplastic LHRH antagonist